Suicide-Gene t cells aim to stop blood cancer relapse

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients HLA-DPB1\*04:01 positive, with confirmed diagnosis of hematologic malignancies (AML, Myelodysplasic and myeloproliferative syndrome, ALL, non-Hodgkin's lymphoma, Hodgkin's disease, CLL), undergoing an allo-HSCT using a HLA-DPB1\*04:01 negative donor. * The graft can be PBSC (peripheric blood stem cells) or bone marrow. * Patients aged between 18-75 years. * Patients in complete remission or \>50% of response (for lymphoma) at time of transplant. * have a donor with no contra-indications for mobilization of peripheral blood stem cells using G-CSF (colony-stimulating factors) * Affiliation number to the National Health Care System * Lack of reactivity of the clone against the donor's cells (PHA-blasts prepared for from PBMCs). * For cord blood transplants: cord blood must be HLA-DPB1\*04:01 negative and the HLA compatibility (A, B, DR) between the cord blood and the recipient must be 4/6, 5/6 or 6/6. * ECOG \<=2 or Karnofsky \>60% * neutrophils ≥ 1 000 cells /μl and/or platelets ≥ 50 000 cells/μl (growth factor allowed) Exclusion Criteria: * pregnant or breastfeeding woman * patient refusing contraception measure * minor * Adult patients under guardianship, curatorship or justice protection * Patients with post-transplant relapse within the clone injection time (before D100) * Karnofsky performance score below 60%or ECOG \>2 * Acute and chronic heart failure (NYHA Class III or IV) or symptomatic ischemic heart disease. * Severe liver failure (bilirubin \>30 µmoles/L, SGPT (Serum Glutamo-Oxalacetic Transaminase)\> 4 X upper limit of normal). * Impaired renal function (creatinine clearance \< 30 ml/min) * Acute GVHD \> grade 1 * Active uncontrolled infection. * Denied to provide informed consent * Severe neurological or psychiatric disorders as determined by the study physician. * Treatment with other investigational drugs following allogeneic transplantation.